|LETTER TO EDITOR
|Year : 2020 | Volume
| Issue : 1 | Page : 141-142
A commentary on outcomes with liquid biopsy to determine the epidermal growth factor receptor mutation status in poor performance status, biopsy-ineligible, advanced non-small cell lung cancer patients
Janani Sambath1, Barnali Deb2, Prashant Kumar2
1 Institute of Bioinformatics, International Technology Park, Bengaluru, Karnataka, India
2 Institute of Bioinformatics, International Technology Park, Bengaluru; Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India
|Date of Submission||31-Dec-2019|
|Date of Acceptance||08-Jan-2020|
|Date of Web Publication||24-Feb-2020|
Faculty Scientist, Institute of Bioinformatics, Discoverer Building, International Technology Park, Whitefield, Bengaluru - 560 066, Karnataka
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Sambath J, Deb B, Kumar P. A commentary on outcomes with liquid biopsy to determine the epidermal growth factor receptor mutation status in poor performance status, biopsy-ineligible, advanced non-small cell lung cancer patients. Cancer Res Stat Treat 2020;3:141-2
|How to cite this URL:|
Sambath J, Deb B, Kumar P. A commentary on outcomes with liquid biopsy to determine the epidermal growth factor receptor mutation status in poor performance status, biopsy-ineligible, advanced non-small cell lung cancer patients. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Aug 5];3:141-2. Available from: https://www.crstonline.com/text.asp?2020/3/1/141/279092
Accurate testing of genomic alterations at the time of diagnosis and at disease progression is a crucial aspect of therapeutic management for the patients. Traditionally, solid tumor tissue biopsy has been considered the gold standard for the detection of molecular alterations in many malignancies including non-small cell lung cancer (NSCLC). However, more recently, isolation and analysis of circulating tumor DNA (ctDNA) from the plasma has emerged as an effective and promising tool for the performance of molecular testing. In a study by Pandey et al., the authors evaluated the outcomes of patients treated on the basis of the epidermal growth factor receptor (EGFR) status determined through liquid biopsy. They further calculated the progression-free survival and overall survival of the patients and observed their treatment based on the liquid biopsy. The findings show a comparable outcome to those of a tissue-based biopsy. The authors used droplet digital polymerase chain reaction-based peripheral blood ctDNA testing, a cost-effective, rapid, and convenient platform for targeted mutation profiling. The study and the accompanying editorial concluded that ctDNA EGFR mutation testing could be a diagnostic tool in biopsy-ineligible advanced metastatic NSCLC.
The authors have used only the samples from the biopsy-ineligible patients; however, the study is based on retrospective observations and must be validated in different cohorts of patients including smokers, nonsmokers, and gender-specific lung cancer patients. The authors also did not follow up the patients over the course of treatment for secondary mutations. Incorporation of such approaches to the study would provide a broader application of the utilization of ctDNA in treatment response. However, ctDNA approach is very timely, accurate, specific, as mutations in ctDNA have been reported to be consistent with those in the tumor DNA.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, et al
. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): A statement paper from the IASLC. J Thorac Oncol 2018;13:1248-68.
Pandey A, Dutt S, Singh A, Kumar A, Singh S. Outcomes with liquid biopsy to determine the EGFR mutation status in poor performance status, biopsy-ineligible, advanced NSCLC patients. Cancer Res Stat Treat 2019;2:197-203. [Full text]
Choughule A, D'Souza H. Liquid biopsy in lung cancer-hope or hype? Cancer Res Stat Treat 2019;2:221-3. [Full text]
Li H, Jing C, Wu J, Ni J, Sha H, Xu X, et al
. Circulating tumor DNA detection: A potential tool for colorectal cancer management. Oncol Lett 2019;17:1409-16.